News
PLRX
1.430
-11.73%
-0.190
Weekly Report: what happened at PLRX last week (0303-0307)?
Weekly Report · 1d ago
Biotech Alert: Searches spiking for these stocks today
TipRanks · 4d ago
Pliant Therapeutics Drops IPF Drug Trial After Review, Analyst Flags Uncertain Future
Benzinga · 6d ago
HC Wainwright & Co. Reiterates Neutral on Pliant Therapeuticsto Neutral
Benzinga · 6d ago
Pliant Therapeutics Is Maintained at Neutral by Citigroup
Dow Jones · 6d ago
Pliant Therapeutics Price Target Cut to $1.50/Share From $4.00 by Citigroup
Dow Jones · 6d ago
Citigroup Maintains Neutral on Pliant Therapeutics, Lowers Price Target to $1.5
Benzinga · 6d ago
Hold Rating on Pliant Therapeutics Amid Trial Discontinuation and Safety Concerns
TipRanks · 6d ago
Pliant Therapeutics Is Maintained at Sector Perform by RBC Capital
Dow Jones · 6d ago
Pliant Therapeutics Price Target Cut to $3.00/Share From $4.00 by RBC Capital
Dow Jones · 6d ago
Pliant downgraded at Stifel on bexotegrast trial discontinuation
Seeking Alpha · 6d ago
RBC Capital Maintains Sector Perform on Pliant Therapeutics, Lowers Price Target to $3
Benzinga · 6d ago
This Teleflex Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday
Benzinga · 6d ago
Okta upgraded, Quest Diagnostics downgraded: Wall Street’s top analyst calls
TipRanks · 6d ago
Pliant Therapeutics Is Maintained at Equal-Weight by Wells Fargo
Dow Jones · 6d ago
Pliant Therapeutics Price Target Cut to $3.00/Share From $4.00 by Wells Fargo
Dow Jones · 6d ago
Wells Fargo Maintains Equal-Weight on Pliant Therapeutics, Lowers Price Target to $3
Benzinga · 6d ago
Analysts Conflicted on These Healthcare Names: Pliant Therapeutics (PLRX) and Capricor Therapeutics (CAPR)
TipRanks · 6d ago
Pliant Therapeutics Price Target Maintained With a $10.00/Share by Needham
Dow Jones · 6d ago
More
Webull provides a variety of real-time PLRX stock news. You can receive the latest news about Pliant Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About PLRX
Pliant Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. Its lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The Company has initiated BEACON-IPF, a Phase 2b trial of bexotegrast in IPF. It has also developed PLN-1474, a small molecule, selective inhibitor of αvß1 integrin for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis. It has initiated a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. The Company has a preclinical program, PLN-101325, targeting muscular dystrophies.